三苯氧胺联合来曲唑治疗ER阳性乳腺癌近期疗效观察  

Short-term efficacy of tamoxifen combined with letrozole in the treatment of ER-positive breast cancer

作　　者：杨莉莎 黄云娜 Yang Lisha;Huang Yunna(Department of Internal Medicine,Shangqiu Municipal Hospital,Shangqiu Henan 476000,China;Department of Oncology,Shangqiu Municipal Hospital,Shangqiu Henan 476000,China)

机构地区：[1]河南省商丘市立医院内科,河南商丘476000 [2]河南省商丘市立医院肿瘤科,河南商丘476000

出　　处：《保健医学研究与实践》2023年第4期37-41,共5页Health Medicine Research and Practice

基　　金：河南省医学科技攻关计划项目(LHGJ201914802)。

摘　　要：目的探讨三苯氧胺联合来曲唑治疗雌激素受体(ER)阳性乳腺癌的近期疗效。方法选取2020年5月—2021年12月商丘市立医院收治的128例ER阳性乳腺癌患者为研究对象,采用随机数字表法分为对照组与观察组,每组64例。对照组患者接受长春瑞滨联合顺铂(NP方案)化疗,同时口服三苯氧胺治疗,观察组患者在对照组基础上口服来曲唑治疗。比较2组患者的疾病控制和不良反应发生情况,同时比较2组患者治疗前后的血清肿瘤标志物和雌二醇(E_(2))表达水平。结果观察组患者治疗后疾病控制率为93.75%(60/64),高于对照组患的75.00%(48/64),差异有统计学意义(χ^(2)=8.533,P=0.003)。2组患者治疗前血清糖类抗原153(CA153)、癌胚抗原(CEA)及雌二醇(E_(2))表达水平比较,差异均无统计学意义(P>0.05);观察组患者治疗后血清CA153、CEA及E_(2)表达水平均低于对照组,差异均有统计学意义(P<0.05)。2组患者胃肠道反应、骨髓抑制、肝肾功能不全及免疫抑制发生率比较,差异均无统计学意义(P>0.05)。结论联合应用三苯氧胺和来曲唑治疗ER阳性乳腺癌患者疗效显著,同时也能够降低患者血清肿瘤标志物的表达水平,有助于控制病情进展,并且在临床实践中证明其安全可靠,值得在临床推广。Objective This paper aims to investigate the short-term efficacy of tamoxifen combined with letrozole in the treatment of estrogen receptor(ER)-positive breast cancer.Methods A total of 128 patients with ER-positive breast cancer admitted to Shangqiu Municipal Hospital from May 2020 to December 2021 were selected and randomly assigned to the control group(n=64)and observation group(n=64).Patients in the control group received vinorelbine combined with cisplatin(NP regimen)chemotherapy and oral tamoxifen,while patients in the observation group were treated with oral letrozole based on the control group.Disease control and adverse reactions were compared between the two groups,and serum tumor markers and estradiol(E_(2))expression levels were also compared between the two groups before and after treatment.Results The disease control rate of the observation group was 93.75%(60/64)after treatment,which was significantly higher than that of the control group[75.00%(48/64),χ^(2)=8.533,P=0.003].There was no significant difference in the expression levels of serum carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),and E_(2) before treatment between the two groups(P>0.05).The expression levels of serum CA153,CEA,and E_(2) after treatment in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of gastrointestinal reactions,bone marrow suppression,liver and kidney dysfunction,and immunosuppression between the two groups(P>0.05).Conclusion Tamoxifen combined with letrozole is effective in the treatment of ER-positive breast cancer,and can also reduce the expression level of serum tumor markers,which is beneficial to control the progression of the disease.It has proved its safety and reliability profiles in clinical practice,hence holding promise for a wider application clinically.

关 键 词：三苯氧胺 来曲唑 雌激素受体阳性 乳腺癌 近期疗效 

分 类 号：R737.9[医药卫生—肿瘤]